Clinical trials: Advanced Tumor
Non-clear Cell Renal Cell Cancer
Study in Non-Clear Cell Renal Carcinoma (Ncc-RCC) Temsirolimus Versus Sunitinib
This will be a prospective, open-label, randomized multicenter phase-II study to evaluate progression free survival (PFS) in patients with locally advanced or metastatic non-clear cell renal cell cancer (ncc-RCC) receiving…
- Trial name
- NCT00979966
- Testing
- Temsirolimus, Sunitinib
- Where
- 14 sites in Germany
- Volunteers
- 22 people
- Sponsor
- Central European Society for Anticancer Drug Research
Unspecified Adult Solid Tumor, Protocol Specific
S-3304 in Treating Patients With Advanced Solid Tumors
RATIONALE: S-3304 may stop or slow the growth of solid tumors by stopping blood flow to the tumor. PURPOSE: Phase I trial to study the effectiveness of S-3304 in treating patients who have solid tumors.
- Trial name
- NCT00033566
- Testing
- S-3304
- Where
- United States
- Sponsor
- Roswell Park Cancer Institute
Adenocarcinoma of the Gastroesophageal Junction, Esophageal Cancer
Panitumumab, Docetaxel, Cisplatin, Radiation Therapy, and Surgery in Treating Patients With Newly Diagnosed, Locally Advanced Esophageal Cancer or Cancer of the Gastroesophageal Junction
RATIONALE: Monoclonal antibodies, such as panitumumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00757172
- Testing
- panitumumab, cisplatin, docetaxel
- Where
- 21 sites in United States
- Volunteers
- 70 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Advanced and/or Metastatic Solid Tumors, Stage IIIB Not Amenable to Curative Therapy to Stage IV Non-small Cell Lung Cancer
INCMGA00012 Plus Chemotherapy in Participants With Advanced Solid Tumors (POD1UM-105)
The purpose of this study is to assess the safety and tolerability and to determine the recommended Phase 2 dose of INCMGA00012 in combination with common standard-of-care chemotherapy regimens in participants with advanced solid…
- Conditions
- Advanced and/or Metastatic Solid Tumors, Stage IIIB Not Amenable to Curative Therapy to Stage IV Non-small Cell Lung Cancer, Advanced/Metastatic Unresectable Malignant Pleural Mesothelioma
- Trial name
- NCT03920839
- Testing
- Retifanlimab, Gemcitabine, Cisplatin
- Sponsor
- Incyte Corporation
HER2positive, Advanced Breast Cancer
Exploratory Study of SHR-A1811 Via Different Administration Routes in Patients
An Exploratory Study on the Efficacy and Safety of Different Administration Routes of SHR-A1811 in the Treatment of HER2-Positive Advanced Breast Cancer
- Conditions
- HER2positive, Advanced Breast Cancer, HER2 + Breast Cancer
- Trial name
- NCT07560475
- Testing
- SHR-A1811
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Locally Advanced Esophageal or GE Junction Cancer
Hypofractionated Definitive Chemoradiotherapy for Oesophageal Cancer
The goal of this clinical trial is to learn if hypofractionation of definitive chemoradiotherapy can treat patients with locally advanced esophageal cancer.
- Trial name
- HYROC (NCT07632079)
- Testing
- Hypofractionation, carboplatin + paclitaxel (CP)
- Where
- 7 sites in Netherlands
- Volunteers
- 60 people
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Follicular Lymphoma
Y90 Ibritumomab Tiuxetan Post R-CHOP Chemotherapy for Advanced Stage Follicular Lymphoma
The primary objective of this study is to establish in a prospective phase II study the efficacy of 90Yttrium ibritumomab tiuxetan (90Y-RIT) after first line induction immuno-chemotherapy with R-CHOP in patients with high-risk…
- Trial name
- ZEVISS (NCT01446562)
- Testing
- Y90 Ibritumomab Tiuxetan RIT
- Where
- Canada
- Volunteers
- 34 people
- Sponsor
- Sunnybrook Health Sciences Centre
Advanced Breast Cancer
Palbociclib Pharmacokinetics Study In Postmenopausal Chinese Women With ER (+), HER2 (-) Advanced Breast Cancer
As part of the global clinical development program for Palbociclib, studies are planned in cancer patients in China. An assessment of Palbociclib pharmacokinetics in Chinese patients, as required by the Chinese Health…
- Trial name
- NCT02499146
- Testing
- Palbociclib, Letrozole
- Where
- 7 sites in China
- Volunteers
- 26 people
- Sponsor
- Pfizer
Renal Cell Carcinoma
Spanish Real-World Evidence Cabozantinib
RCC (Renal Cell Carcinoma) is the most common form of kidney cancer, accounting for 2-3% of all adult malignancies and for 90% of all kidney cancers.
- Trial name
- SRWEC (NCT04510688)
- Testing
- Cabozantinib
- Where
- 32 sites in Spain
- Volunteers
- 275 people
- Sponsor
- Spanish Oncology Genito-Urinary Group
Rectal Cancer, Rectal Neoplasms
Organ Preservation in Locally Advanced Rectal Cancer by Radiochemotherapy Followed by Consolidation Chemotherapy.
There is a growing body of evidence that surgery and associated morbidities can be omitted without compromising oncological safety in selected patients who have achieved a clinical complete response after radiochemotherapy.
- Conditions
- Rectal Cancer, Rectal Neoplasms, Rectal Cancer Stage II, Rectal Cancer Stage III
- Trial name
- CAO/ARO/AIO-16 (NCT03561142)
- Testing
- Radiotherapy, Chemotherapy, Deep regional hyperthermia
- Where
- 4 sites in Germany
- Volunteers
- 94 people
- Sponsor
- University Hospital Tuebingen
Cancer
Specialized Palliative Telemedicine for Patients with Advanced Cancer
Specialized palliative care (SPC) plays an important role in providing patient-centered care and support to informal caregiver, besides establishing/intensifying/coordinating collaboration with primary and secondary health care…
- Trial name
- TeleSPC (NCT05231070)
- Testing
- TeleSPC
- Where
- Denmark
- Volunteers
- 60 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Advanced Solid Tumor, Ovarian Cancer
First in Human Study of TORL-1-23 in Participants With Advanced Cancer
This first-in-human study will evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of TORL-1-23 in patients with advanced cancer
- Conditions
- Advanced Solid Tumor, Ovarian Cancer, Endometrial Cancer, NSCLC
- Trial name
- NCT05103683
- Testing
- TORL-1-23
- Where
- 14 sites in United States, South Korea
- Volunteers
- 90 people
- Sponsor
- TORL Biotherapeutics, LLC
Advanced Malignant Solid Neoplasm, Recurrent Ependymal Tumor
Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)
This phase II Pediatric MATCH trial studies how well ulixertinib works in treating patients with solid tumors that have spread to other places in the body (advanced), non-Hodgkin lymphoma, or histiocytic disorders that have a…
- Conditions
- Advanced Malignant Solid Neoplasm, Recurrent Ependymal Tumor, Recurrent Ewing Sarcoma, Recurrent Glioma
- Trial name
- NCT03698994
- Testing
- Pharmacokinetic Study, Ulixertinib
- Where
- 107 sites in United States, Puerto Rico
- Volunteers
- 20 people
- Sponsor
- National Cancer Institute (NCI)
Small Cell Lung Cancer (SCLC)
Spanish Real World Data on Patients Treated With Durvalumab After Chemoradiotherapy.
This is a non-interventional, observational, multicentre, one-arm, non-comparative, and retrospective study. The study is based on the collection of data about the patients treated with Durvalumab after chemoraditherapy in the…
- Trial name
- S-REAL (NCT04285866)
- Testing
- Durvalumab
- Where
- 39 sites in Spain
- Volunteers
- 245 people
- Sponsor
- Fundación GECP
Advanced, Malignant Aerodigestive Tract Tumor (Lung, Head and Neck and Esophagus)
Erlotinib (Tarceva) and Bexarotene (Targretin) Oral Capsules in Advanced Cancers of the Aerodigestive Tract
Primary objective: To determine the Phase II doses and to evaluate the safety of administering bexarotene (Targretin®) daily in combination with oral erlotinib (Tarceva™) to patients with advanced aerodigestive tract cancers.
- Trial name
- NCT01116622
- Testing
- Bexarotene (Targretin®), Erlotinib (Tarceva™)
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Gastric Carcinoma Stage IV
XELOX Versus FOLFOX for Advanced Gastric Cancer (AGC)
The purpose of this study is to identify the non-inferiority of the combination therapy of Capecitabine and Oxaliplatin compared with the combination therapy of Fluorouracil/Folinic acid and Oxaliplatin in patients with advanced…
- Trial name
- NCT01748851
- Testing
- XELOX, FOLFOX
- Where
- South Korea
- Volunteers
- 42 people
- Sponsor
- Dong-A University Hospital
Advanced Cancer
The Efficacy of Multisession Mindful Breathing in Symptom Reduction Among Patients With Advanced Cancers
The goal of this clinical trial is to determine the efficacy of multisession mindful breathing in reducing symptoms among patients with advanced cancer.
- Trial name
- NCT05910541
- Testing
- Mindful breathing, Standard care (control)
- Where
- Malaysia
- Volunteers
- 80 people
- Sponsor
- University Malaysia Sarawak
Pancreatic Adenocarcinoma, Homologous Recombination Deficiency
Cisplatin to Patients With Pancreatic Cancer and Homologous Recombination Deficiency
The purpose of this study is to evaluate the efficacy of cisplatin based regimen to patients with advanced pancreatic cancer and homologous recombination deficiency.
- Trial name
- PTCA199-6 (NCT06095141)
- Testing
- Cisplatin
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Fudan University
Tumor, Adenocarcinoma
A Pilot Study to Assess Changes in Tumor Biology Following Second-line Treatment With Pembrolizumab Plus Lenvatinib in Patients With Advanced Pancreatic Ductal Adenocarcinoma
This is a clinical research study to learn if pembrolizumab in combination with lenvatinib can help to control pancreatic ductal adenocarcinoma.
- Trial name
- NCT05273554
- Testing
- Pembrolizumab, lenvatinib
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- M.D. Anderson Cancer Center
Intrahepatic Cholangiocarcinoma, FGFR2 Gene Mutation
Pemigatinib After Curative Local Therapy in Advanced iCCA With FGFR2 Fusion/Rearrangements
The aim of this phase II study is to determine whether pemigatinib is clinically efficious after curative local therapy such as surgery/ SBRT or ablation in iCCA patients harboring FGFR2 fusion/rearrangement and to assess the…
- Conditions
- Intrahepatic Cholangiocarcinoma, FGFR2 Gene Mutation, FGFR2 Gene Rearrangement, FGFR2 Gene Translocation
- Trial name
- NCT05565794
- Testing
- Pemigatinib
- Where
- 10 sites in Germany
- Volunteers
- 2 people
- Sponsor
- Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.